Rise Therapeutics Reports Ulcerative Colitis Dose Escalation Clinical Results for R-3750 at the Digestive Disease Week (DDW) Conference in San Diego May 3–6

Results highlight safety and promising clinical responses of R-3750, along with biomarker results demonstrating a differentiated immune mechanism

UF startup Rise Therapeutics, a biopharmaceutical company developing precision immunotherapies, announced that it will report its first clinical results from the completed dose escalation segment of its R-3750 Phase 1 clinical trial in ulcerative colitis at the upcoming DDW conference in San Diego on May 6th.

R-3750, a novel oral immunotherapy, is a synthetic biology-based medicine in development for the treatment of Inflammatory Bowel Disease (IBD). Optimized to selectively target dendritic cells, R-3750 is a first-in-class therapy with a unique mechanism of action with the potential to treat the underlying immunological basis of gastrointestinal inflammatory diseases. Dysfunctional immune control is an important underlying mechanism driving IBD. Extensive preclinical studies on R-3750 demonstrated targeting of a specific dendritic cell receptor which promotes regulatory T cell (Treg) induction, reduces gut inflammation, and improves gut membrane barrier integrity.

Read more about Rise Therapeutics Reports Ulcerative Colitis Dose Escalation Clinical Results for R-3750 at the Digestive Disease Week (DDW) Conference in San Diego May 3–6.